“`html
Tharimmune (NASDAQ:THAR), a clinical-stage biotech firm honing in on immunology and inflammation therapies, has announced the pricing of a $1.74 million registered direct public offering. The package includes 414,331 shares of common stock and 559,910 pre-funded warrants, plus 974,241 warrants to purchase common stock at a strike price of $1.66 per share.
Investors will acquire units—each comprising one share of common stock or a pre-funded warrant and a common warrant—at $1.786 apiece. President Street Global, LLC is acting as the exclusive placement agent, tasked with navigating the deal. The transaction anticipates a close around July 25, 2025, funneling proceeds into working capital and supporting general corporate endeavors.
Tharimmune (NASDAQ:THAR), una società biotecnologica in fase clinica, ha annunciato il prezzo di un offerta pubblica diretta registrata da 1,74 milioni di dollari di azioni ordinarie e warrant. L’offerta comprende 414.331 azioni ordinarie e 559.910 warrant pre-finanziati, insieme a 974.241 warrant per l’acquisto di azioni ordinarie a un prezzo di esercizio di 1,66 dollari per azione.
Le unità, composte da una azione ordinaria o warrant pre-finanziato e un warrant ordinario, sono quotate a 1,786 dollari per unità. President Street Global, LLC è l’agente di collocamento esclusivo. La chiusura dell’offerta è prevista intorno al 25 luglio 2025, con i proventi destinati al capitale circolante e a scopi societari generali.
Tharimmune (NASDAQ:THAR), una empresa biotecnológica en etapa clínica, ha anunciado la fijación del precio de una oferta pública directa registrada de 1,74 millones de dólares de acciones comunes y warrants. La oferta incluye 414,331 acciones comunes y 559,910 warrants prefinanciados, junto con 974,241 warrants para adquirir acciones comunes a un precio de ejercicio de 1,66 dólares por acción.
Las unidades, que comprenden una acción común o un warrant prefinanciado y un warrant común, tienen un precio de 1,786 dólares por unidad. President Street Global, LLC actúa como agente de colocación exclusivo. Se espera que la oferta cierre alrededor del 25 de julio de 2025, destinando los ingresos a capital de trabajo y propósitos corporativos generales.
Tharimmune (NASDAQ:THAR)는 임상 단계의 바이오테크 회사로서, 174만 달러 규모의 등록 직접 공개 발행 주식 및 워런트 가격을 발표했습니다. 이번 발행에는 414,331주 보통주와 559,910개 선납 워런트, 그리고 974,241개 워런트가 포함되며, 행사 가격은 주당 1.66달러입니다.
단위는 보통주 또는 선납 워런트 1주와 보통 워런트 1주로 구성되며, 단위당 1.786달러에 가격이 책정되었습니다. President Street Global, LLC가 독점 배치 대행사로 활동합니다. 이번 발행은 2025년 7월 25일경 마감될 예정이며, 자금은 운전자본 및 일반 법인 목적에 사용될 예정입니다.
Tharimmune (NASDAQ:THAR), une société biotechnologique en phase clinique, a annoncé le prix d’une offre publique directe enregistrée de 1,74 million de dollars d’actions ordinaires et de bons de souscription. L’offre comprend 414 331 actions ordinaires et 559 910 bons de souscription préfinancés, ainsi que 974 241 bons permettant d’acquérir des actions ordinaires à un prix d’exercice de 1,66 dollar par action.
Les unités, composées d’une action ordinaire ou d’un bon préfinancé et d’un bon ordinaire, sont proposées au prix de 1,786 dollar par unité. President Street Global, LLC agit en tant qu’agent de placement exclusif. La clôture de l’offre est prévue aux alentours du 25 juillet 2025, les fonds étant destinés au fonds de roulement et à des fins générales d’entreprise.
Tharimmune (NASDAQ:THAR), ein Biotechnologieunternehmen in der klinischen Entwicklungsphase, hat die Preisfestsetzung einer registrierten Direktplatzierung im Wert von 1,74 Millionen US-Dollar von Stammaktien und Optionsscheinen bekannt gegeben. Das Angebot umfasst 414.331 Stammaktien und 559.910 vorfinanzierte Optionsscheine sowie 974.241 Optionsscheine zum Erwerb von Stammaktien zu einem Ausübungspreis von 1,66 US-Dollar je Aktie.
Die Einheiten, bestehend aus einer Stammaktie oder einem vorfinanzierten Optionsschein und einem Stammoptionsschein, sind zu 1,786 US-Dollar pro Einheit bepreist. President Street Global, LLC fungiert als exklusiver Platzierungsagent. Der Abschluss des Angebots wird voraussichtlich um den 25. Juli 2025 erfolgen, wobei die Erlöse für das Betriebskapital und allgemeine Unternehmenszwecke vorgesehen sind.
Positive
- Secured $1.74 million in additional funding for working capital
- Strategic placement through President Street Global enhances distribution
Negative
- Potential dilution for existing shareholders through new share issuance
- Offering price of $1.786 represents a discount to market price
- Additional dilution possible through warrant exercises
Insights
Tharimmune’s small $1.74M offering likely indicates cash constraints for this clinical-stage biotech, suggesting operational challenges ahead.
Tharimmune’s $1.74 million registered direct offering reveals concerning capital dynamics for this clinical-stage immunology biotech. The relatively small offering size is particularly troubling for a Nasdaq-listed company developing therapies in the capital-intensive immunology space. This financing appears inadequate for substantial clinical advancement, suggesting it’s primarily for short-term operational needs rather than meaningful pipeline progression.
The offering structure combines common stock, pre-funded warrants, and common warrants at $1.786 per unit with additional warrants exercisable at $1.66. This complex structure with warrants typically indicates challenging fundraising conditions. The company explicitly states proceeds are for “working capital and general corporate purposes” rather than specific clinical milestones, reinforcing the impression this is stopgap financing.
Notably, the offering represents substantial dilution relative to Tharimmune’s market capitalization. The involvement of President Street Global as placement agent on a “reasonable best-efforts basis” rather than a firm commitment underwriting further suggests limited institutional interest. For clinical-stage biotechs, fundraising capacity directly impacts development timelines and strategic options. This modest raise likely provides only limited runway, potentially necessitating additional dilutive financings in the near future unless the company achieves significant value-creating milestones.
07/23/2025 – 10:15 PM
RED BANK, NJ / ACCESS Newswire / July 23, 2025 / Tharimmune, Inc. (THAR) is tapping the market with a $1.74 million registered direct public offering, injecting capital into the clinical-stage biotech specializing in immunology and inflammation. The offering encompasses a mix of securities: 414,331 common shares, 559,910 pre-funded warrants, and 974,241 warrants exercisable at $1.66 per share, all structured within a Securities Purchase Agreement.
Strategic Investors and Placement Details
The offering is projected to yield approximately $1.74 million before accounting for placement agent fees and other expenses. Tharimmune plans to deploy these funds into bolstering working capital and for general operational expenses, prioritizing flexibility in a volatile biotech landscape.
President Street Global, LLC, is serving as the exclusive placement agent, operating on a reasonable best-efforts basis. This arrangement speaks to both the opportunities and challenges present in securing capital for firms in the clinical development phase.
The closing of the offering is slated for around July 25, 2025, contingent upon standard closing conditions. This financial maneuver underscores Tharimmune’s strategic bid to maintain momentum in its therapeutic pipeline.
Regulatory Details
The offering falls under a shelf registration statement previously filed with the SEC, effective since March 24, 2023. The common stock and underlying shares from pre-funded warrants are made available exclusively through a prospectus, accessible on the SEC’s website. Before investing, prospective buyers should review the preliminary prospectus supplement and accompanying prospectus for thorough details on Tharimmune and the offering terms.
Furthermore, the common warrants are offered under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, noting that these warrants and their underlying shares have not been registered under the Securities Act or state securities laws. Tharimmune has committed to filing a resale registration statement to enable future trading upon appropriate registration, acknowledging the critical need for regulatory compliance in capital markets.
This announcement does not constitute a sales offer or investment solicitation. Sales are void in jurisdictions where such activity is unlawful prior to registration or qualification under local securities laws.
About Tharimmune, Inc.
Tharimmune is focused on creating therapies in immunology, inflammation, and oncology. Its primary clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression. This aims at military personnel and chemical incident responders exposed to high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis, and TH023, a new approach to treating autoimmune diseases, along with an early-stage multispecific biologic platform through its EpiClick™Technology.
Forward Looking Statements
This release contains forward-looking statements subject to the Private Securities Litigation Reform Act of 1995, including forecasts regarding future trials, strategies, operations, financial standings, costs, and management objectives. Terms like “anticipate,” “believe,” and “expect,” signal these statements, yet outcomes may vary significantly due to risks detailed in Tharimmune’s SEC filings. The company does not commit to updating these statements in light of new developments.
FAQ
What is the size and structure of Tharimmune’s (THAR) July 2025 offering?
Tharimmune’s offering consists of $1.74 million in securities, including 414,331 common shares, 559,910 pre-funded warrants, and 974,241 warrants exercisable at $1.66 per share.
What is the price per unit in THAR’s registered direct offering?
Each unit in the offering is priced at $1.786, consisting of one share of common stock or pre-funded warrant plus a common warrant.
When will Tharimmune’s (THAR) registered direct offering close?
The offering is expected to close on or about July 25, 2025, subject to customary closing conditions.
How will Tharimmune (THAR) use the proceeds from the offering?
Tharimmune plans to use the net proceeds for working capital and general corporate purposes.
Who is the placement agent for Tharimmune’s (THAR) offering?
President Street Global, LLC is acting as the exclusive placement agent for the offering on a reasonable best-efforts basis.
